Viatris offers value with high free cash flow and dividends but faces growth challenges from legacy drug price erosion and ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

Valued at a market cap of $10.8 billion, Viatris Inc. (VTRS) is a healthcare company headquartered in Canonsburg, ...

Viatris has aggressively deleveraged, now poised for growth with a robust pipeline. See why a Strong Buy rating is justified ...

Viatris's phase 3 trial for pimecrolimus 0.3% in blepharitis failed to meet its primary endpoint of debris resolution after ...

Viatris’ investigational blepharitis ointment failed to achieve the primary endpoint in its Phase III trial, prompting the ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

Viatris' Phase 3 trial for pimecrolimus 0.3% in blepharitis did not meet its primary goal, prompting the company to reassess ...

Viatris said on Friday that its experimental eye ointment failed to clear buildup or debris in the eyes in a late-stage study in patients with an inflammatory eye condition.

Shares of Viatris Inc. VTRS advanced 1.41% to $9.37 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.78% to 6,358.91 and ...

Viatris Inc. closed 34.10% below its 52-week high of $13.55, which the company achieved on November 25th.